Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 in myelofibrosis, indolent systemic mastocytosis, and mast cell activation syndrome
NL-OMON59468Phase 2Not yet recruiting
- Sponsor
- Telios Pharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of TL-895 in myelofibrosis (MF), indolent systemic mastocytosis (ISM) and Mast Cell Activation Syndrome (MCAS) (5 arms), sponsored by Telios Pharma. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
TL-895
03
Conditions
myelofibrosis (MF)indolent systemic mastocytosis (ISM)Mast Cell Activation Syndrome (MCAS)
Beyond the preview
Go deeper on NL-OMON59468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59468.